Azitra, Inc., a pre-clinical biopharmaceutical company, focuses on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It is developing ATR-12, a genetically modified strain of S. epidermidis for treating Netherton syndrome, a skin disease; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. The company was incorporated in 2014 and is based in Branford, Connecticut.

Employees - 12, CEO - Francisco D. Salva, Sector - Healthcare, Country - US, Market Cap -

Altman ZScore(max is 10): -24.51, Piotroski Score(max is 10): 0, Working Capital: $1951361, Total Assets: $5025386, Retained Earnings: $-68521196, EBIT: -10207118, Total Liabilities: $1224156, Revenue: $0

- Current Price $ - Analyst Target Price $